"This not going to be an expensive vaccine," Hill told Reuters in an interview. It's going to be made for global supply and it's going to be made in many different locations. The experimental vaccine, known as ChAdOx1 nCoV-19, is one of the front runners in the global race to provide protection against the new coronavirus causing the COVID-19 pandemic. Hill's team began early-stage human trials of the vaccine in April, making it one of only a handful to have reached that milestone. "The ambition is shared to get a low-priced, very, very extensively available vaccine as soon as possible," Hill said.

Source: bd News24 May 15, 2020 14:37 UTC